Effect of Selenium Supplement on the progress of 2 diabetes

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029184

Enrollment

Unknown

Registered

2020-01-17

Start date

2020-03-02

Completion date

Unknown

Last updated

2020-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prediabetes

Interventions

Experimental group:Selenium supplement

Control group:placebo

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Permanent residents living in Shenzhen for six months and aged 18-65 years; 2. Fasting blood glucose level is between 6.1 and 7.0mmol/L or glycosylated hemoglobin is less than 6.5%.

Exclusion criteria

Exclusion criteria: 1. hypertension or diabetes; 2. taking or have recently taken medications or supplements that affect the results of the study; 3. Low compliance to quit halfway; 4. trauma and surgery (within 6 months); 5. Severe heart, brain and liver functions and other endocrine diseases affecting glucose metabolism; 6. other reasons to quit halfway.

Design outcomes

Primary

Measure	Time frame
Glucose;glycosylated hemoglobin;blood pressure;serum lipid;Blood Se levels;routine urine;Stool Routine;	—

Countries

China

Contacts

Public ContactXiaolin Peng

Shenzhen Nanshan Centre for Chronic Disease Control

25731738@qq.com+86 18218818612

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026